Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

COVID-19 Systematic Mini-Review as of April 2025

*Corresponding Author:

Received Date: Apr 03, 2025 / Accepted Date: Apr 22, 2025 / Published Date: Apr 29, 2025

Copyright: © 0  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 
To read the full article Peer-reviewed Article PDF image

Abstract

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2), primarily affects the respiratory system, leading to a broad spectrum of pulmonary complications. The pathophysiology of COVID-19 in the lungs includes direct viral injury, hyper inflammatory responses, endothelial dysfunction, and thrombosis. This article reviews the mechanisms of lung involvement, clinical manifestations, imaging findings, and therapeutic approaches with a focus on severe and critical cases of COVID-19. We provide an in-depth discussion on Acute Respiratory Distress Syndrome (ARDS), pulmonary fibrosis, pulmonary vascular complications, and the long-term pulmonary sequelae in post-COVID-19 patients. Current and emerging therapeutic strategies, including antivirals, corticosteroids, immunomodulators, anticoagulants, and mechanical ventilation approaches, are analyzed. This comprehensive review aims to provide insights into the pulmonary impact of COVID-19 and future research directions.

Keywords

Top